China’s official PMIs jumped back into expansionary territory

China’s official NBS PMIs bounced back in March. The manufacturing PMI rose to 52.0, up from 35.7, while the non-manufacturing increased to 52.3 after 29.6 in February. By their very construction, a strong rebound had to be expected. PMI surveys essentially ask whether firm’s businesses have been better or worse compared to the previous month.

Highlights:

  • This morning, China’s official NBS manufacturing and non-man. PMIs jumped back into expansionary territory.
  • While this confirms China’s economy has likely started to bottom out from the Covid-19 crisis, the outlook will depend on three factors:
    • The ongoing normalization in production and consumer demand: While production will likely reach normal capacity utilization in mid-April (provided new corona cases remain on low levels) private consumption is still lagging.
    • The global recession: We strongly revised down our 2020 global GDP forecasts (to -1%) which will result in weak Chinese exports.
    • An additional fiscal package: Last Friday’s politburo meeting fueled expectations that a package will be announced shortly. We expect total stimulus of around 3.5% – 4% of GDP.
  • In sum, we see China’s growth subdued this year at 2.5%. We stress that this forecast comes with an unusually high degree of uncertainty.

Download the full publication below

CHINA’S OFFICIAL PMIS JUMPED BACK INTO EXPANSIONARY TERRITORY

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.